CA3243526A1 - THERAGNOSTICS FOLATE CONJUGATES - Google Patents

THERAGNOSTICS FOLATE CONJUGATES

Info

Publication number
CA3243526A1
CA3243526A1 CA3243526A CA3243526A CA3243526A1 CA 3243526 A1 CA3243526 A1 CA 3243526A1 CA 3243526 A CA3243526 A CA 3243526A CA 3243526 A CA3243526 A CA 3243526A CA 3243526 A1 CA3243526 A1 CA 3243526A1
Authority
CA
Canada
Prior art keywords
compound according
radiometal
compound
dota
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243526A
Other languages
English (en)
French (fr)
Inventor
Viola Groehn
Marie-Luise RENZ
Rudolf Moser
Roger Schibli
Cristina Magdalena Mueller
Martina BENESOVA
Patrycja GUZIK
Luisa Maria Deberle
Anna Elisabeth BECKER
Sara Dorina BUSSLINGER
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3243526A1 publication Critical patent/CA3243526A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3243526A 2022-02-01 2023-01-30 THERAGNOSTICS FOLATE CONJUGATES Pending CA3243526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154653.4 2022-02-01
EP22154653 2022-02-01
PCT/EP2023/052116 WO2023148115A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
CA3243526A1 true CA3243526A1 (en) 2023-08-10

Family

ID=80119142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243526A Pending CA3243526A1 (en) 2022-02-01 2023-01-30 THERAGNOSTICS FOLATE CONJUGATES

Country Status (9)

Country Link
US (1) US20250108138A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504028A (cg-RX-API-DMAC7.html)
KR (1) KR20240142514A (cg-RX-API-DMAC7.html)
CN (1) CN118660723A (cg-RX-API-DMAC7.html)
AU (1) AU2023214599A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243526A1 (cg-RX-API-DMAC7.html)
IL (1) IL314507A (cg-RX-API-DMAC7.html)
WO (1) WO2023148115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025220711A1 (ja) * 2024-04-17 2025-10-23 日本メジフィジックス株式会社 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物
WO2026014283A1 (ja) * 2024-07-09 2026-01-15 日本メジフィジックス株式会社 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物

Also Published As

Publication number Publication date
CN118660723A (zh) 2024-09-17
AU2023214599A1 (en) 2024-09-19
EP4472676A1 (en) 2024-12-11
US20250108138A1 (en) 2025-04-03
IL314507A (en) 2024-09-01
JP2025504028A (ja) 2025-02-06
WO2023148115A1 (en) 2023-08-10
KR20240142514A (ko) 2024-09-30

Similar Documents

Publication Publication Date Title
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
AU2014336638B2 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
JP2002515462A (ja) 診断および治療用途に用いるホレート誘導化金属錯体
EP2948186A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US20250108138A1 (en) Theragnostic folate conjugates
WO2026040780A1 (zh) 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
Ruser et al. Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111
US20250127938A1 (en) Theragnostic folate conjugates
WO2025195225A1 (zh) 一种靶向fgl1的多肽及其应用
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
HK40110380A (en) Theragnostic folate conjugates
HK40109744A (en) Theragnostic folate conjugates
JP2024530057A (ja) ネトリン-1検出、コンパニオン検査及び放射線に基づく療法
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
EP4282439A1 (en) Radioisotope labeled sstr2-agonists with linkers
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
HK40054611A (en) Novel tumor antigen binding agents and uses thereof
HK40080502B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Jackson et al. Molecular Imaging of Breast Cancer Tissue via Site-Directed Radiopharmaceuticals

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240730

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240731

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240731

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241002

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217